Clinical Trial Update: Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users [Phase 4]

View source ↗

Summary

Phase 4 clinical trial of buprenorphine extended-release subcutaneous injection (RBP-6000) for high-risk individuals with moderate to severe opioid use disorder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• SUBLOCADE (buprenorphine extended-release)

Snippet

Sponsor: Indivior Inc. | Conditions: Moderate to Severe Opioid-use Disorder | Phase 4 | Status: COMPLETED | Results posted: 2025-09-25